How Remote Patient Monitoring Can Help Advance Health Equity
It’s an unfortunate reality of the US healthcare system that health disparities have long persisted across multiple years and populations,...
Health
At ViVE, How Did VCs Respond to Criticism of Their Industry?
From left to right: Lee Shapiro, Emily Melton, Richard Mulry, Ambar Bhattacharyya and Arundhati Parmar Digital health funding in the...
Atropos Health Launches Evidence Network to Back Its Physician Consult Service
When caring for patients with rare and/or complex conditions, physicians often don’t know exactly what to do. During appointments, they’re...
The Power of Patient Preference in Shaping the Drug Delivery Market
Photo by Flickr user Jernej Furman When it comes to medicine, catering to convenience and patient preference can have life-changing...
J&J Portfolio Review Culls RSV Vaccine, Ending the Phase 3 Program
Respiratory syncytial virus vaccines could be approved and ready for arms by next fall, but a Johnson & Johnson shot...
It’s Time to Raise Our Voice for Interpreter Reimbursement in Healthcare
Accessing medical care in a time of distress is scary enough when you understand the language the doctors and nurses...
Aneesh Chopra: VBC Will Bring ‘Radical’ Transparency to Healthcare for These 3 Reasons
The healthcare system has seen “modest growth” in the last couple years in terms of the race to achieve 100%...
The Areas That Intermountain Health’s CIO Wants To Address With Technology (And the One He Doesn’t)
Man fingers setting priority button on highest position. Concept image for illustration of priorities management. Salt Lake City-based Intermountain Health...
The Case Against a Portfolio Approach in Biotech
In recent years, numerous biotech companies have adopted a portfolio approach with the promise that this strategy both diversifies risk...
Novartis Puts Up $50M to Steer Bicycle Therapeutics’ Tech Into New Cancer Meds
Bicycle Therapeutics’ novel approach to developing peptide drugs has produced several cancer clinical-stage drug candidates. Now Novartis wants to see...
